- Home
- RNR vs ITCI Comparison
RNR vs ITCI Comparison
Compare RNR & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNR
- ITCI
- Stock Information
- Founded
- RNR 1993
- ITCI 2002
- Country
- RNR Bermuda
- ITCI United States
- Employees
- RNR N/A
- ITCI N/A
- Industry
- RNR Property-Casualty Insurers
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- RNR Finance
- ITCI Health Care
- Exchange
- RNR Nasdaq
- ITCI Nasdaq
- Market Cap
- RNR 13.4B
- ITCI 13.5B
- IPO Year
- RNR 1995
- ITCI N/A
- Fundamental
- Price
- RNR $226.18
- ITCI $128.60
- Analyst Decision
- RNR Hold
- ITCI Buy
- Analyst Count
- RNR 11
- ITCI 13
- Target Price
- RNR $279.90
- ITCI $103.92
- AVG Volume (30 Days)
- RNR 554.5K
- ITCI 2.2M
- Earning Date
- RNR 01-28-2025
- ITCI 02-21-2025
- Dividend Yield
- RNR 0.71%
- ITCI N/A
- EPS Growth
- RNR N/A
- ITCI N/A
- EPS
- RNR 35.21
- ITCI N/A
- Revenue
- RNR $11,771,224,000.00
- ITCI $613,728,000.00
- Revenue This Year
- RNR N/A
- ITCI $48.28
- Revenue Next Year
- RNR $4.25
- ITCI $37.34
- P/E Ratio
- RNR $6.41
- ITCI N/A
- Revenue Growth
- RNR 28.28
- ITCI 46.08
- 52 Week Low
- RNR $208.98
- ITCI $63.30
- 52 Week High
- RNR $300.00
- ITCI $128.77
- Technical
- Relative Strength Index (RSI)
- RNR 33.63
- ITCI 83.90
- Support Level
- RNR $228.66
- ITCI $126.88
- Resistance Level
- RNR $233.76
- ITCI $128.19
- Average True Range (ATR)
- RNR 4.81
- ITCI 0.41
- MACD
- RNR -0.35
- ITCI -1.30
- Stochastic Oscillator
- RNR 5.43
- ITCI 91.01
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.